Correction: FDA-Transplant Drug story
|Report an Error|
Share via Email
TRENTON, N.J. — In a story Nov. 8 about a new drug approval, The Associated Press misspelled the drug's name. It is Prevymis, not Prevymix.
A corrected version of the story is below:
FDA OKs drug to block infection after marrow transplant
U.S. regulators approve new drug to prevent life-threatening infections in adults after a bone marrow transplant
BY LINDA A. JOHNSON
AP Medical Writer
U.S. regulators have approved the first drug to prevent life-threatening infections in adults after a bone marrow transplant.
The Food and Drug Administration on Wednesday approved sales of Merck and Co.'s Prevymis (PREH'-vih-miss) to prevent infections with cytomegalovirus (sy-toe-MEG'-a-low-vy-rus), a common virus. It doesn't sicken most people, but strikes at least half of transplant patients, who are particularly vulnerable to infection. The virus can damage the eyes, lungs and other organs, trigger pneumonia and even kill.
Kenilworth, New Jersey-based Merck says the drug will cost $195 to $270 per day for 100 days.
Each year, about 8,500 Americans receive transplants of blood-forming cells from bone marrow to treat blood cancers or other blood disorders. Currently, they get antiviral therapy if they develop an infection, rather than a preventive treatment.
This story has been corrected to show that the name of the approved drug is Prevymis, not Prevymix.
More on Metronews.ca
Take stock of your debts and devise a plan to pay them off while saving as much on interest as you can.
Three ways to tell that you aren't a great bargain hunter, but consumed by shopping instead.